Prognostic Factors for Long-Term Eribulin Response in a Cohort of Patients With HER2-Negative Metastatic Breast Cancer.
Fiche publication
Date publication
juin 2024
Journal
Clinical breast cancer
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BORG Christophe, Dr CHAIGNEAU Loïc, Dr MENEVEAU Nathalie, Mr MONNIEN Franck, Dr WORONOFF Anne-Sophie, Dr CURTIT Elsa, Dr MANSI Laura, Dr VERNEREY Dewi, Dr SELMANI Zohair, Dr MOLIMARD Chloé, Mr FALCOZ Antoine
Tous les auteurs :
El Kaddissi A, Vernerey D, Falcoz A, Mansi L, Bazan F, Chaigneau L, Dobi E, Goujon M, Meneveau N, Paillard MJ, Selmani Z, Viot J, Molimard C, Monnien F, Woronoff AS, Curtit E, Borg C, Meynard G
Lien Pubmed
Résumé
Eribulin is used in taxane and anthracycline refractory HER2-negative metastatic breast cancers (MBC). Patients treated in pivotal clinical trials achieved low survival rates, therefore, the identification of prognostic criteria for long progression-free survival (PFS) is still an unmet medical need. In this study, we sought to determine potential prognostic criteria for long-term eribulin response in HER2-negative MBC.
Mots clés
Eribulin, MDM2, Metastatic breast cancer, long response, nomogram
Référence
Clin Breast Cancer. 2024 06 19;: